@dansfera: Ever wonder why your small biopharma startup feels like a ghost at the table when working with massive CROs? Here is a brutal reality check on industry prioritization. When a CRO is juggling a decades-long pipeline for a giant like Eli Lilly, the resources are never going to flow toward the smaller players. It’s a classic case of getting lost in the shuffle—and the frustration from emerging biotechs is completely valid. It turns out, size really does matter when it comes to getting the attention you’re paying for. #biotech #biopharma #startupbusiness #CRO #lifesciences
And if you are a new company and you pick a relatively well respected CRO you should listen to them since they’ve done how many trials? And things your first phase 3? If you won’t listen to the CRO maybe listen to the sites when the entire giant conference room groans at a statement. Maybe listen then? That way 15 months into the trial you aren’t running into the exact problems everyone listed above warned you about. (Sorry…. I have pent up frustration)
2026-09-03 02:20:00
0
To see more videos from user @dansfera, please go to the Tikwm
homepage.